Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) and Orano Med said first patients were dosed in a US Phase 1/2a trial of DLL3-targeting 212Pb Radio-DARPin MP0712. Five US sites are recruiting; dosing is ongoing in cohort 1 with repeat dosing. Initial data are expected in 2026 and fuller safety/efficacy in 2027 (NCT07278479).
How this was made
The 30-second read
Why it matters
The announcement confirms trial activation (first patients dosed, cohort 1 recruited and moving to repeat dosing) and reiterates expected initial data timing (2026) and more comprehensive efficacy/safety dataset (2027).
Market read
This is a primary clinical milestone for MP0712, likely to support near-term sentiment for MOLN while awaiting initial data later in 2026.
What to watch
Key risk remains cohort safety/tolerability and whether imaging/dosimetry translates into meaningful tumor uptake; no quantitative outcomes are provided here.
Background
Molecular Partners and Orano Med are running a US multicenter Phase 1/2a trial of MP0712, a DLL3-targeting Radio-DARPin carrying 212Pb, using a matched-pair imaging/therapy approach.
Ticker impact
Molecular Partners says first patients were dosed in the US Phase 1/2a study of its DLL3-targeting Radio-DARPin MP0712 with 212Pb payload.
Potentially supportive for near-term sentiment, but likely modest unless follow-on safety/efficacy readouts are strong.
The release is a primary clinical milestone (first dosing, cohort 1 repeat dosing, sites recruiting) but provides no efficacy/safety results yet; typical biotech reaction is sentiment-driven until data.
Market effects
Adds incremental momentum to targeted alpha therapy (212Pb) and Radio-DARPin platforms; may modestly lift peer sentiment around early-stage radiopharma execution.
US trial sites recruiting; could influence US-listed biotech sentiment more than Europe-only names.
Cross-border collaboration (Switzerland/US and France) highlights continued global investment in alpha-emitter radioligands.
Counterpoint
First dosing is an operational milestone, not a clinical efficacy signal; investors may fade the news ahead of the first data window.
Key entities
- companyMolecular Partners AG
Clinical-stage DARPin therapeutics company developing MP0712.
- companyOrano Med
Clinical-stage radiopharmaceutical company providing 212Pb-based targeted alpha therapies and collaborating on MP0712.
- drug_candidateMP0712
DLL3-targeting Radio-DARPin carrying 212Pb; being tested in US Phase 1/2a.
- clinical_trialNCT07278479
ClinicalTrials.gov identifier for the US multicenter Phase 1/2a study.
